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Summary
We report the identification of a new locus for autosomal
dominant limb-girdle muscular dystrophy (LGMD1) on
7q. Two of five families (1047 and 1701) demonstrate
evidence in favor of linkage to this region. The maxi-
mum two-point LOD score for family 1047 was 3.76
for D7S427, and that for family 1701 was 2.63 for
D7S3058. Flanking markers place the LGMD1 locus
between D7S2423 and D7S427, with multipoint anal-
ysis slightly favoring the 9-cM interval spanned by
D7S2546 and D7S2423. Three of five families appear
to be unlinked to this new locus on chromosome 7, thus
establishing further heterogeneity within the LGMD1
diagnostic classification.
Introduction
Limb-girdle muscular dystrophy (LGMD), which has an
incidence of ∼1/100,000 (Yates and Emery 1985), en-
compasses a clinically diverse group of disorders char-
acterized by proximal muscle weakness first affecting the
hip and shoulder girdle, elevated creatine kinase values,
and absent or reduced deep-tendon reflexes. Both re-
cessive (Jackson and Strehler 1968; Shokeir and Ko-
brinski 1976) and dominant (Chutkow et al. 1986;
Gilchrist et al. 1988) forms have been reported, as have
sporadic cases (Morton and Chung 1959).
Extensive locus heterogeneity has been demonstrated
in the autosomal recessive LGMDs, with eight loci cur-
rently identified, including six cloned genes (Beckmann
et al. 1991; Bashir et al. 1994; Bonnemann et al. 1995;
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Noguchi et al. 1995; Moreira et al. 1997; Liu et al.
1998). The extent of heterogeneity within the dominant
LGMDs mirrors that observed in the recessive form.
Speer et al. (1992) were the first to localize a form of
dominant LGMD to 5q (LGMD1A [MIM 159000]) and
to demonstrate evidence for locus heterogeneity (Speer
et al. 1995) within the autosomal dominant LGMDs.
Unique to the 5q-linked family is a dysarthric speech
pattern, present in ∼50% of affected family members.
Three additional autosomal dominant LGMD loci have
been localized. LGMD1B (MIM 159001) (van der Kooi
et al. 1997), found in pedigrees from the Netherlands,
Surinam, and the Carribbean, with a cardiac conduc-
tion-system defect affecting the atrial-ventricular node
and with congestive heart failure in some patients, has
been localized to 1q11-21. LGMD1C (MIM 601253),
located at 3p25, is caused by a defect in caveolin 3
(McNally et al. 1998; Minetti et al. 1998). A third
LGMD1 locus, in a family with familial dilated car-
diomyopathy and a cardiac conduction-system defect,
has been located on 6q23 (CDCD3 [MIM 602067])
(Messina et al. 1997). We have continued to characterize
our unlinked LGMD1 families and now report identi-
fication of a new LGMD1 locus on 7q and establish
evidence for further linkage heterogeneity within this
diagnostic classification.
Subjects and Methods
Family Ascertainment and Diagnostic Classification
Diagnostic classification for LGMD has been estab-
lished elsewhere (Speer et al. 1992). In brief, individuals
were considered affected when they had progressive
proximal leg weakness with or without proximal arm
weakness, absent ankle deep-tendon reflexes, and ele-
vated creatine kinase values. The diagnostic evaluation
of at least one affected member per family documented
a myopathic process. Neither electromyography nor
muscle biopsy demonstrated any pathognomonic fea-
tures of other disorders.
Individuals with normal examination results and with
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Table 1
Family Data and Simulated Z Values for LGMD1 Pedigrees
FAMILY







383 27 9 1.10 (.02) 3.00
1047 32 11 1.82 (.04) 4.88
1701 63 22 3.25 (.05) 9.47
1767 20 9 1.01 (.02) 2.61
1970 11 4 .59 (.01) 1.36
Figure 1 Multipoint linkage analysis for families 1701and1047,
for the full-pedigree and low-penetrance analyses.
creatine kinase levels within normal limits were assigned
gene-carrier risks based on their age at examination. The
probability that an individual carries the LGMD1 gene
was generated from a normal distribution, by use of the
mean age at onset in the families ( years).27.1 8.5
Family members who have signs or symptoms suggestive
of LGMD1 but who do not meet the strictly defined
diagnostic criteria were considered to be of unknown
disease status. All spouses were considered normal with
respect to clinical status. Clinical information was
scanned optically into the PEDIGENE database (Haynes
et al. 1995). Informed consent was obtained from all
study participants. This study has been approved by the
Duke University Medical Center institutional review
board.
Studies to determine the power of the available ped-
igree material were performed by SIMLINK (Boehnke
1986; Ploughman and Boehnke 1989). For these simu-
lations, we used a model similar to that for the linkage
analysis. We further assumed the availability of a te-
traallelic marker with heterozygosity of .70, linked at
5% recombination with the disease locus. One thousand
replicates were performed.
DNA Collection and Genotyping for Genomic
Screening
For DNA extraction, a minimum of 24 ml of blood
was collected in either EDTA or acid citrate–dextrose
tubes, by venipuncture of participating individuals. Each
sample was assigned a consecutive sample number, was
entered into PEDIGENE, and was identified by that
number subsequently, for all genotyping analyses. DNA
was extracted from the lymphocytes in the DNA bank
of the Center for Human Genetics (CHG), by use of
standard protocols (Vance 1998).
One hundred thirty-five prelabeled multiplex primer
sets (comprising 430 primers) were used for the initial
genomic screening set and provided an ∼7-cM screen of
the genome. Plates were amplified on either MJ DNA
engines or Hybaid Omnigenes and then were loaded
onto a 110-lane dual-gel C.B.S. electrophoretic unit, for
size separation, by means of a Hamilton syringe.
The gels were then scanned on an Hitachi FMBIO II,
and the image was downloaded to the CHG network.
Allele size was determined semiautomatically by the
whole-band analysis program of BIOIMAGE. The geno-
types were then downloaded into PEDIGENE. The in-
tegrity of the genotyping data was assessed routinely, via
standard quality-control checks.
Haplotype Analysis and Identification of the Minimum
Candidate Region (MCR)
Haplotype analysis, in which the ordered genetic
markers surrounding the region of interest were assigned
the most likely chromosomal configurations (haplo-
types), was performed to identify critical recombination
events between affected individuals. This haplotype
analysis was both performed by hand and confirmed
numerically by SimWalk (Weeks et al. 1995). Genetic
marker genotypes for critical recombination events we
confirmed on an independent DNA sample (blood spots,
buccal swabs, or an additional blood sample), when
possible.
Statistical Analysis
Two-point and multipoint LOD score (Z) values were
calculated by the VITESSE computer program (Weeks
et al. 1995). Both a full-pedigree analysis and an “af-
fecteds-only” analysis were performed. The full-pedigree
analysis requires specification of a penetrance model and
incorporates all the available phenotypic and genotypic
data, allowing the pedigree material to be maximally
informative. The affecteds-only analysis utilizes the phe-
notypic data only on those individuals whose diagnostic
status is most certain—that is, the affected individuals.
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ANALYSISTwo-Point Z Value at v 
Zmax
(Supportˆv
Interval).00 .05 .10 .15 Zmax ˆv
D7S1815:
383 6.568 1.694 1.127 .804 NA NA NA NA
1047 1.277 1.164 1.046 .925 1.277 .00 (.00–.40) .573 .00
1701 99.999 .561 .667 .646 .667 .10 (NA) .751 .10
1767 3.944 .234 .020 .068 NA NA NA NA
1970 99.999 1.726 1.147 .819 NA NA NA NA
D7S3058:
383 .232 .200 .170 .142 NA NA NA NA
1047 1.599 1.398 1.196 .995 1.599 .00 (.00–.26) 1.512 .00
1701 1.619 2.080 2.568 2.627 2.627 .15 (.03–.33) 5.236 .00
1767 99.999 .614 .088 .158 NA NA NA NA
1970 99.999 3.387 2.262 1.618 NA NA NA NA
D7S427:
383 2.388 1.538 .946 .600 NA NA NA NA
1047 3.762 3.351 2.931 2.504 3.762 .00 (.00–.12) 2.037 .00
1701 99.999 1.696 .347 .217 .438 .20 (NA) 1.955 .10
1767 99.999 .463 .231 .119 NA NA NA NA
1970 99.999 1.721 1.143 .815 NA NA NA NA
NOTE.—NA  not applicable.
The genotypic marker data on all family members was
retained in the analysis, to maximize the ability to infer
genotypes from deceased relatives. Significant evidence
in favor of linkage was declared when the Z at any value
of the recombination fraction (v) was greater than or
equal to the standard Z score of 3.0. 1-Z-unit support
intervals for the maximum-likelihood estimate of v were
calculated from two-point Z values, by means of the
1-Z-down method (Ott 1991).
Marker alleles were estimated from a series of 25
unrelated individuals from an ethnically and geograph-
ically matched control population. These allele frequen-
cies and relevant CEPH standards are available from the
Duke Center for Human Genetics (Duke University
Medical Center). Assessment of heterogeneity of the Z
values was performed by means of the admixture test,
as implemented in the HOMOG package (Ott 1991).
Results
Power-study results for the available family material
are presented in table 1. Of the five families, three (383,
1047, and 1701) have the capability of generating a Z
3.0 whereas the remaining two (1767 and 1970) can
yield Z values of 2.52 and 1.36.
Genomic screening identified an area of interest on
chromosome 7. Two point Z values for our five families,
for markers D7S1815, D7S3058, and D7S427, are
shown in table 2. For the full-pedigree model, the peak
Z (Zmax) of 3.76 for family 1047 occurs for marker
D7S427 at . For family 1701, the Zmax of 2.63v  .00
occurred for D7S3058 at . The three remainingv  .15
families (383, 1767, and 1970) yielded negative or un-
informativeZ values for markers in this region. Analyses
performed under the low penetrance or “affecteds-only”
model were consistent with the above interpretation, and
in addition provided significant evidence for linkage of
family 1701 to this region of chromosome 7 (Z max
; ). Evidence for linkage andˆ5.24 maximum v [v]  .00
for heterogeneity was significant when D7S3058, the
most informative marker, was used in this low-pene-
trance model ( ; ). A multipoint anal-2x  5.85 P  .0081
ysis performed in all five families, using the map
D7S1815–D7S3058–D7S427 with the low-penetrance
model, identified two families (1047 and 1701) to be
linked with 195% probability. The remaining three fam-
ilies yielded posterior probabilities of linkage !10%, as
well as negative Z values, throughout the bulk of the
interval. Thus, additional genotyping to identify themin-
imum candidate interval for the disease gene was limited
to families 1047 and 1701.
Families 1047 and 1701 were subsequently genotyped
for polymorphic markers between D7S1815 and
D7S427, to refine the disease-gene interval. Multipoint
linkage analysis was performed with the map
D7S1805–11.8 cM–D7S2546–8.9 cM–D7S2423–9.1
cM–D7S427. In the full-penetrance analysis, the overall
Zmax was 7.40 when the disease gene was placed between
D7S2546 and D7S2423; family 1047 has a Zmax of 4.93,
and family 1701 has a Zmax of 3.68. This location is
supported over the next most likely location, between
D7S2423 and D7S427, with odds of 10:1. Under the
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Figure 2 Selected subset of pedigree 1047, demonstrating the proximal breakpoint of D7S2546. This recombination event likely occurred
in transmission from affected individual 1000 to affected son 0120. The blackened bars represent areas of chromosome 7 that harbor the
LGMD1 gene in this family. Establishment of linkage phase was performed visually and was confirmed with SimWalk (Weeks et al. 1995).
Inferred genotypes are in parentheses. Note that markers D7S637 and D7S2546 are linked at 0% recombination.
low-penetrance model, the Zmax obtained for family
1047 was 3.85, and that for family 1701 was 7.57, with
an overall Zmax of 11.00 in the same interval as in the
full-pedigree analysis (fig. 1).
Analysis of the recombination events in affected fam-
ily members confirmed that current flanking markers are
D7S2546 (fig. 2) proximally and D72423 (fig. 3) distally.
Specifically, a recombination event distal to D7S2546 is
evident in individuals 9012 and 9011 in family 1047;
minimization of the recombination events in this family
implies that the event occurred in the transmission from
individual 1000 to individual 0120. In family 1701, a
recombination event occurred proximal to D7S2423 in
individual 0115. Interpretation of this distal breakpoint
in family 1701, however, is complicated by the fact that
the only difference between the disease-associated hap-
lotype and the “recombinant” interval occurs at
D7S2423, suggesting that the 247 allele may possibly
represent a new mutation. If that is the case, the distal
breakpoint for this gene may be D7S427 (fig. 3), thereby
increasing the size of the interval to 18 cM. Individual
8004 in family 1047 was asymptomatic and was 25
years old at the time of examination, well below the
average age at onset in this family, and thus the recom-
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Figure 3 Subset of family 1701, demonstrating a recombination event in 0115 that confirms the distal breakpoint of D7S2423. Estab-
lishment of linkage phase was performed visually and was confirmed with SimWalk (Weeks et al. 1995). The most likely linkage phases are in
parentheses. Note that markers D7S637 and D7S2546 are linked at 0% recombination.
bination event in this individual cannot currently be
evaluated. Interestingly, families 1701 and 1047 share a
common haplotype for the disease-associated region,
suggesting that a common ancestor links the two pedi-
grees. However, family histories through the preceding
three generations fail to identify a common ancestor.
Discussion
We have established evidence for linkage of two large
LGMD1 pedigrees to 7q, in the 9-cM interval spanned
by D7S2546 and D7S2423. This new LGMD1 gene lies
in the terminal region of chromosome 7. Odds for sup-
port of this localization, however, are weak (10:1 over
next most likely interval), because of the pedigree struc-
ture (earlier generations of the pedigrees are unavaila-
ble), limiting the ability to accurately assign linkage
phase. Recruitment of additional family members is cur-
rently underway to fully refine the interval. Interestingly,
several members of family 1701 are asymptomatic and
likely are gene carriers, on the basis of haplotype anal-
ysis. These individuals include four (ages 27, 33, 34, and
34 years ) who are either at or above the average age
at onset and two individuals (ages 6 and 21 years) who
are below the average age at onset. Their inclusion in
the linkage analysis utilizing an age-at-onset curve serves
to lower the Z values in the full-pedigree analysis, com-
pared with that in the affecteds-only analysis.
In addition, we have established additional underlying
linkage heterogeneity within the LGMD1 classification.
Clinically, all five pedigrees demonstrate identical pat-
terns of muscle weakness in affected individuals; the only
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discernible difference among the pedigrees is that family
1767 demonstrates earlier age at onset (mean SD 
) than is seen in the other pedigrees.6 2.3 years
Clinical data on linked families 1047 and 1701 has
been published previously (Schneiderman et al. 1969;
Speer et al. 1995). Clinically, these families differ from
other linked LGMD1 families, in their lack of other as-
sociated findings. For instance, in addition to the char-
acteristic patterns of muscle weakness, the chromosome
5–linked LGMD1A family has a unique dysarthric
speech pattern, and the chromosome 6–linked (van der
Kooi et al. 1997) and chromosome 1–linked families
(Messina et al. 1997) have associated cardiac abnor-
malities. Age at onset is similar (i.e., onset occurs in
adulthood) in all linked families—with the exception of
those in which the disease is due to mutations in cav-
eolin-3, which have onset during childhood (Minetti et
al. 1998).
Interestingly, the extensive heterogeneity evident
within the autosomal dominant LGMDs closely mirrors
that characterized in the autosomal recessive LGMDs.
In the autosomal recessive LGMDs, six genes have been
cloned that are involved in disease development, and
four of them are known to be small transmembrane
proteins, components of the sarcoglycan complex. This
finding has allowed elucidation of an entire family of
proteins that serve a previously unknown function in the
dystrophin-glycoprotein complex. Thus, the autosomal
recessive LGMDs have transformed this group of dis-
eases from a diffuse clinical “collection of illnesses” into
a group providing seminal data about the pathophy-
siology of the dystrophin-glycoprotein complex. The fur-
ther characterization of the autosomal dominant
LGMDs promises similar insights, and the clarification
of the phenotypic similarities between these genetically
different entities will undoubtedly shed light on impor-
tant muscle pathologies.
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